Aridis Pharmaceuticals Announces A Pan-Coronavirus Monoclonal Antibody Cocktail That Retains Effectiveness Against The Omicron variant, Other COVID-19 Variants, SARS, MERS, And The Common Cold Human Coronaviruses

AR-701 cocktail binds to the Omicron variant with similar effectiveness as to the original Wuhan strain

Viral neutralization and animal infection models support broad prophylaxis and therapeutic efficacy of AR-701 against SARS-CoV-2 and SARS

Aridis Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced that its fully human monoclonal antibody (mAb) cocktail AR-701 is broadly reactive against the Omicron and other COVID-19  variants, SARS , MERS (Middle East Respiratory Syndrome Coronavirus), and seasonal (‘common cold’) human coronaviruses.

Recommended AI News : Metatron Announces Agreement with Real Estate Blockchain Platform

• AR-703, one of the components of the AR-701 cocktail, binds to the ‘S2’ stalk region of coronavirus spike proteins that is responsible for viral fusion and entry into host cells, and binds to the Omicron variant with no loss in affinity as compared to the original Wuhan strain.
• In vitro neutralization studies using live coronaviruses showed that AR-701 achieved broad, potent neutralization against all SARS-CoV-2 variants tested, as well as SARS, MERS, and the seasonal ‘common cold’ betacoronaviruses.
• In vivo data with multiple animal challenge models that are widely used to evaluate COVID-19 treatments support AR-701’s broad efficacy.
• AR-701 is engineered to be long-acting, and is expected to provide relevant drug levels for up to 1 year from prophylactic or therapeutic treatment.

Recommended AI News: Mobilum Technologies Signs Agreement To Integrate Off-Ramp Services Into The Ledger Live Platform, Gateway For Digital Assets & Web3

“Omicron has rendered current COVID-19 vaccines and monoclonal antibodies substantially less effective, and likely future COVID 19 variants will arise that continue this trend” said Vu Truong, Ph.D., Chief Executive Officer of Aridis Pharmaceuticals. “AR-701 is the result of our successful search for a mAb therapy that is directed against a conserved region of the virus that would be less vulnerable to mutations and new variants such as Omicron. Our laboratory data suggest that AR-701 has the potential to be a future-proof COVID-19 therapy that can protect against SARS-CoV-2, SARS, or MERS pandemics,” continued Dr. Truong. “To our knowledge AR-701 is the only COVID-19 therapy that targets two distinct viral mechanisms of action, making it much harder for the virus to generate resistance, and exhibits an unmatched combination of broad reactivity and high efficacy,” continued Dr. Truong.

Recommended AI News: C Ventures Backed RTFKT to be Acquired by NIKE

[To share your insights with us, please write to sghosh@martechseries.com]